Leadership Team

Philippe Lamarre CEO

A Message from our CEO

For most of us, we need to look no further than our own families to have been impacted by degenerative diseases, chronic health conditions, and cancers that often appear with a terminal prognosis. Yet, I hope that it is fair to say that for many of us, we have been lucky enough to have benefited from drugs, therapies, and products that have alleviated some or all of the debilitating characteristics of these ailments.

 I certainly have experienced the wonders of scientific progress in fighting disease and prolonging the quality life for loved ones, and count myself blessed to be part of a team of dedicated and caring individuals that participate in this medical progress.

Mispro Biotech Services is in the enviable position of serving as a catalyst for such critical scientific research and development. Our core business of managed research environments enables biotech organizations to launch and control early-stage animal studies in stable & secure facilities without having to incur the costs of building or operating a private vivarium. Which allows for more organizations to launch studies for their discoveries, and when more scientists are at work, more advancements in health care can be made. Of this, we believe our business model makes both economic and scientific sense, and we are currently expanding our network of facilities to enable more organizations to pursue development of their therapeutic products.

But it is our support of these organizations in the pursuit of good science that we are most proud, and from which Mispro operates its entire business model. Our managed facilities would not be as attractive an option for conducting early-stage development research without the expert animal care, compliance oversight, and operational excellence that we offer to our clients. Mispro also strongly supports and advocates for the ethical & humane treatment of research animals, and we are dedicated to pursuing, and ensuring, the 3R’s in every study conducted in our facilities & with our Insource services. Our clients are conducting important, powerful work, and Mispro is committed to being their most valuable research partner.


Keith M. Astrofsky, DVM

Vice President of Operations & Capital Asset Development

As Vice President of Operations & Capital Asset Development, Dr. Astrofsky is responsible for managing Mispro’s daily operations, including facilities, staff, and services. Dr. Astrofsky has more than 20 years’ experience in veterinary & animal laboratory sciences, with expertise in animal care & welfare, program accreditation & compliance, animal model development, husbandry & technical procedures, and animal facility design.

Prior to joining Mispro, Dr. Astrofsky was Executive Director & Global Head, Laboratory Animal Services (LAS) at Novartis Institutes for Biomedical Research (NIBR). Previous to that, he served as Attending Veterinarian & Head, Vivarium Operations with Praecis Pharmaceuticals, Inc. Dr. Astrofsky is an active member of several professional societies & committees and continues to serve in consulting, teaching, and advisory positions with several biotechnology, non-profit, and academic institutions.

Dr. Astrofsky received his DVM from Tufts University School of Veterinary Medicine and completed a postdoctoral fellowship in comparative medicine at the Massachusetts Institute of Technology (MIT) in the laboratory of James G. Fox, DVM.


Yohan Tessier

Vice President of Commercial Operations & Strategic Development

As Vice President of Commercial Operations & Strategic Development, Yohan is responsible for managing the Strategic Development, Sales & Marketing division of Mispro. Since 2007, Yohan has been on the forefront of Mispro’s growth from a single site in Montréal to the company’s current network of multiple facilities in key U.S. biotech clusters.

With several years’ experience in big pharma and a background in science & healthcare, Yohan has an acute understanding of the challenges associated with drug development. His tireless enthusiasm for identifying opportunities & solutions to support the life sciences industry in the pursuit of drug therapies has been a cornerstone in establishing Mispro as a leader in space & services solutions for in-vivo science.

Yohan recently completed the Executive MBA programs at ESG-UQAM/Paris –Dauphine universities and has also received a B.Sc. in Biochemistry from McGill University.

denis (2)

Denis Archambault

chief financial officer

Kelly Perlangeli

Vice President, human resources

Anouk Laurent

corporate counsel

George Skourides

Director of Business Development


Bill Glencross

Director of Sales


John Fogarty

Director of Marketing


Moses Gutierrez rlatg, cmar

Associate Director of Operations


Claire Johnson ms, cpia

Manager of Quality Assurance & Compliance; IACUC Chair


Elizabeth Horrigan Bs, LATg

Manager of Technical Services


Andrea C. Bresnick, MPH

Client Relationship Manager

Cristian (1)

Cristian Ramos​​



Alexandre Dame​​

Director of Information Technology​

Yan_new (2)

Yan Morin, rlat

Site Supervisor


Benny Lapierre AS, alat

Site Supervisor


Edgar Castro aa, rlat

Site Supervisor


Mark D. Snead bs, ralat

Site Supervisor


Ryan Dominia AS, alat

Site Supervisor